Treatment Selection Between FLAURA2 and MARIPOSA

Both panelists acknowledge that most academic centers now adopt combination regimens as standard practice, with the TOP study providing additional supportive evidence rather than fundamentally changing treatment approaches. However, the data proves particularly valuable for clinicians who must prioritize resources or convince patients about combination therapy benefits.

Dr. Olazagasti typically favors FLAURA2 approaches because patients often feel more comfortable with traditional chemotherapy regimens, and practical considerations sometimes necessitate starting chemotherapy before EGFR mutation results are available. In high symptom burden situations with oxygen requirements, initiating chemotherapy immediately followed by osimertinib addition upon mutation confirmation provides clinical flexibility.

Dr. Rodriguez notes increased experience with both regimens has revealed significant nuance in treatment selection. Some patients prefer chemotherapy-free approaches, particularly given subcutaneous amivantamab's convenience with monthly dosing requiring only 12 annual visits versus chemotherapy's 3-week cycles involving 4+ hour infusion center stays.

However, the MARIPOSA regimen demands substantial patient engagement, especially during the first 4 months. Despite optimal prophylactic dermatologic management and reduced infusion reaction rates with subcutaneous formulations, patients experience more intensive toxicity management requiring careful preparation and monitoring.

The panelists emphasize that both regimens require comprehensive patient education about expected side effects and management strategies. FLAURA2 may cause fatigue cycles where patients spend 3 days in bed post-chemotherapy, while MARIPOSA involves more visible skin toxicity requiring extensive prophylaxis and monitoring.

Real-world data suggests toxicity intensity peaks during the first 4 months of amivantamab therapy, with subsequent management becoming less intensive and rash incidence decreasing significantly after this initial period. additional follow-up.